LeMaitre Vascular Q1 sales $53.5M (+14%), EPS $0.44 (+62%); raises FY op. margin guidance to 22%

LEMAITRE VASCULAR INC

2024-Q1 EPS reported $0.44 revenue$53,478,000

Q1 net income $9.9M (+64%); gross margin 68.6% (+300 bps) on price increases and manufacturing efficiencies.
Allografts (+31%), carotid shunts (+27%), and APAC sales (+44%) led growth; organic sales +11%.
Board declared $0.16/share dividend payable May 30 to holders of record May 16.
FY 2024 guided sales $212.7-217.3M (+11%), EPS $1.73-1.84 (+33% vs. FY 2023), operating margin 22%.
Share repurchase program of up to $50M authorized through Feb 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

LEMAITRE VASCULAR INC reported the quarter ended March 31, 2024 results: revenue $53.5mm, net income $9.9mm, EPS $0.44. Guidance reaffirmed.

Period: the quarter ended March 31, 2024
Revenue: $53.5mm
Net income: $9.9mm
EPS: $0.44
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2024 results, announced a $0.16/share quarterly dividend and provided guidance. Q1 2024 Financial Results ● Sales $53.5mm, +14% (+11% organic) vs. Q1 2023 ● Gross margin 68.6%, +300 bps ● Op. income $11.9mm, +51% ● Op. margin 22% ● Net income $9.9mm, +64% ● Earnings per diluted share $0.44, +62%

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

LEMAITRE VASCULAR INC filing history →

Source: SEC EDGAR

accession 0001437749-24-014372

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.